In this study, we performed a NMA to evaluate the safety of first-line PD-L1 inhibitors monotherapy in advanced NSCLC positive PD-L1 patients compared to platinum-based chemotherapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.